You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
专家指辉瑞疫苗防疫功效尚有多项问题待解
阿思达克 11-10 11:27
《路透》报道,辉瑞(PFE.US)及BioNTech(BNTX.US)研发新冠疫苗预防有效率为九成以上,指有关数据基於94名志愿者感染新冠病毒而得出,有效率是以受感染者当中被注射安慰剂人士比率作计算。

报道引述专家指,有关测试仍有大量问题待解,包括疫苗能否预防严重个案或并发,疫苗防疫持久性及对长者的功效,并指疫苗的安全数据要在本月稍後才能得出,辉瑞及BioNTech亦未提交报告予其他科学家检视。报道同时引述专家指,美国食品及药物管理局早前亦下调中期数据标准,放宽需要有5宗严重个案的要求。

辉瑞及BioNTech的测试预定有164名志愿者感染确诊,预计确诊数字将於12月第一或第二周达标,美国食品及药物管理局以外的独立专家届时将检视结果并建议是否采用该疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account